
Imlunestrant Plus Abemaciclib Improves Progression-Free Survival in Patients With ER+, HER2- Advanced Breast Cancer
Imlunestrant (Eli Lilly and Company) plus abemaciclib (Verzenio; Eli Lilly and Company) significantly improved progression-free survival (PFS) in patients with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) …